Riversedge Advisors
REGN icon

Riversedge Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Riversedge Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$582K Buy
768
+378
+97% +$286K 0.07% 126
2026
Q2 		$243K Buy
390
+31
+9% +$21.1K 0.03% 263
2026
Q1 		$277K Sell
359
-12
-3% -$9.19K 0.04% 156
2025
Q4 		$286K Buy
+371
New +$252K 0.05% 151

Other funds holding REGN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Riversedge Advisors's REGN Position: Q3 2026 in Review

Riversedge Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 97% in Q3 2026, buying an estimated $286K and bringing the position to 768 shares worth $582K. The position accounts for 0.07% of the portfolio, ranked #126.

Riversedge Advisors first reported a position in REGN in Q4 2025 and has held it in 4 quarters since. 895 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Riversedge Advisors held 768 shares of Regeneron Pharmaceuticals worth $582K as of Q3 2026.
  • Riversedge Advisors bought 378 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $286K.
  • Regeneron Pharmaceuticals made up 0.07% of Riversedge Advisors's portfolio in Q3 2026, its #126 holding.
  • Riversedge Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 895 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Riversedge Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.